Trial Profile

A Phase 2, Open-Label, Single-Arm, 156-week Trial to Investigate the Efficacy, Safety and Tolerability of Combined Once Weekly Navepegritide and Lonapegsomatropin in Children With Achondroplasia

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 25 Feb 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Lonapegsomatropin (Primary) ; Navepegritide (Primary)
Indications Achondroplasia
Focus Adverse reactions; Proof of concept; Therapeutic Use
Acronyms COACH
Sponsors Ascendis Pharma

Most Recent Events

18 Feb 2026 Planned End Date changed from 1 Sep 2027 to 1 Nov 2027.
18 Feb 2026 Planned primary completion date changed from 1 Sep 2025 to 14 Nov 2025.
09 Jan 2026 According to an Ascendis Pharma media release, Week 78 COACH data update anticipated in second quarter of 2026.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com